• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Sunshine’s Adva-27a study results

Sunshine’s Adva-27a study results

July 11, 2011
CenterWatch Staff

Sunshine Biopharma, a development stage pharmaceutical company, has completed a detailed cytotoxicity study of its lead compound, Adva-27a, in MCF-7/MDR, a Multidrug Resistant Breast Cancer cell line.  Cytotoxicity studies measure the ability of a drug to destroy cancer cells in vitro.  The results showed that Adva-27a is 16 times more effective at killing Multidrug Resistant Breast Cancer cells than Etoposide, the current commonly used drug.  Data generated by the study revealed that Adva-27a is unaffected by the molecular machinery which are responsible for making cancer cells resistant to drugs.

Dr. Steve N. Slilaty, Sunshine’s president and CEO, said cancer cells become resistant to anti-tumor drugs by overproducing a protein called P-Glycoprotein. Encoded by the ABCB1 gene (also called the MDR1 gene), P-Glycoprotein is a trans-membrane enzyme that binds and transports drugs to the outside of cancer cells, making them resistant. P-Glycoprotein  pumps out most, if not all, antineoplastics including doxorubicin,  vinblastine, gemcitabine, etoposide, paclitaxel, etc.

The data showed P-Glycoprotein cannot bind and transport Adva-27a.  “Previously unavailable, Adva-27a offers a chemical structure that can be used as a basis for studying the mechanism of action of P-Glycoprotein as well as for the development of new drugs that can overcome the resistance caused by P-Glycoprotein and similar  enzymes,” Dr. Slilaty said.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing